English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu
The Food and Drug Administration on June 7 approved Aducanumab, which will carry the brand name Aduhelm, as the first new treatment for Alzheimer’s disease in nearly 20 years.
Dr. Jeffrey L. Cummings, UNLV research professor and leading expert on Alzheimer’s clinical trials, calls Aducanumab a “breakthrough therapy,” with three other drugs in the pipeline looking promising, too. The analysis is part of Cummings’ work leading the world’s only research observatory devoted exclusively to Alzheimer’s disease clinical trials and drug development.
For the past five years, Cummings and his team have completed a comprehensive analysis of the pipeline of drugs in clinical trials for the treatment of Alzheimer’s disease and other dementias.
Dr. Cummings is available to offer insight into the current landscape of Alzheimer’s clinical trials, including the historic June 7 FDA approval of Aduhelm (aducanumab).
Prior to UNLV, Dr. Cummings served as founding director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, and as director of the Mary S. Easton Center for Alzheimer’s Disease Research and the Deane F. Johnson Center for Neurotherapeutics, both at UCLA.
